MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by Allspring Global Investments Holdings LLC


Allspring Global Investments Holdings LLC decreased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCTGet Rating) by 0.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 344,005 shares of the company’s stock after selling 2,187 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.34% of MaxCyte worth $1,627,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Freemont Management S.A. acquired a new stake in MaxCyte during the first quarter worth $68,000. Nkcfo LLC acquired a new stake in shares of MaxCyte in the first quarter valued at $91,000. Ensign Peak Advisors Inc acquired a new stake in shares of MaxCyte in the first quarter valued at $137,000. Strs Ohio grew its stake in shares of MaxCyte by 588.9% in the first quarter. Strs Ohio now owns 24,800 shares of the company’s stock valued at $173,000 after buying an additional 21,200 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of MaxCyte in the first quarter valued at $204,000. Institutional investors and hedge funds own 66.40% of the company’s stock.

Insiders Place Their Bets

In other MaxCyte news, major shareholder Casdin Partners Master Fund, L sold 735,786 shares of MaxCyte stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $6.15, for a total transaction of $4,525,083.90. Following the completion of the sale, the insider now directly owns 10,000,000 shares of the company’s stock, valued at approximately $61,500,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Thomas M. Ross sold 4,282 shares of the business’s stock in a transaction dated Tuesday, October 11th. The stock was sold at an average price of $6.51, for a total value of $27,875.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 735,786 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $6.15, for a total value of $4,525,083.90. Following the completion of the sale, the insider now directly owns 10,000,000 shares of the company’s stock, valued at $61,500,000. The disclosure for this sale can be found here. 5.11% of the stock is owned by company insiders.

MaxCyte Trading Up 4.2 %

NASDAQ:MXCT opened at $5.99 on Friday. The firm has a market cap of $610.40 million, a PE ratio of -29.95 and a beta of 0.42. The stock has a fifty day moving average price of $6.02 and a 200 day moving average price of $5.34. MaxCyte, Inc. has a 12-month low of $3.36 and a 12-month high of $12.99.

MaxCyte (NASDAQ:MXCTGet Rating) last released its earnings results on Wednesday, August 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $9.61 million during the quarter, compared to analyst estimates of $9.00 million. MaxCyte had a negative return on equity of 7.60% and a negative net margin of 47.92%. Equities analysts forecast that MaxCyte, Inc. will post -0.29 EPS for the current year.

Analysts Set New Price Targets

Separately, BTIG Research lifted their price objective on MaxCyte from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Sunday, August 14th.

About MaxCyte

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Read More

Institutional Ownership by Quarter for MaxCyte (NASDAQ:MXCT)



Receive News & Ratings for MaxCyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MaxCyte and related companies with MarketBeat.com’s FREE daily email newsletter.

Read more here: Source link